Company Overview and News

1
Gifts That Keep On Giving: Is Backdating Back? : TheCorporateCounsel.net Blog

2018-01-03 thecorporatecounsel.net
Last month, the WSJ published an investigative report that suggested that hundreds of corporate insiders frequently had uncanny timing when it came to gifts of company stock.
Upvote Downvote

 
UNILIFE EX-99.1

2017-08-02 sec.gov
EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE   In re     Unilife Corporation, et al. [1]    Case No.                     17-10805                         Reporting Period: June 1 to June 30, 2017 MONTHLY OPERATING REPORT File with Court and submit copy to United States Trustee within 20 days after end of month Submit copy of report to any official committee appointed in the case.
Upvote Downvote

 
UNILIFE FORM 8-K (Current Report/Significant Event)

2017-08-02 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K      CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2017     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)       Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
Ampoules and Syringes Market, Plastic Ampoules, Cyclic Olefin Copolymers, and Cyclic Olefin Polymers; Syringe Product Type - Polymer Syringes and Glass Syringes - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

2017-07-10 prnewswire
LONDON, July 10, 2017 /PRNewswire/ -- Global Ampoules and Syringes Market: Overview This report provides forecast and analysis of the ampoules and syringes market on the global and regional level. The study provides historic data of 2015 along with forecast from 2016 to 2024 based on volume (Mn Units) and revenue (US$ Mn). It includes drivers, restraints and the ongoing trend of the ampoules and syringes market along with their impact on demand during the forecast period.
Upvote Downvote

 
UNILIFE EX-99.1

2017-06-26 sec.gov
unis-ex991_6.htm Exhibit 99.1 Case 17-10805-LSS Doc 229 Filed 06/22/17 Page 1 of 14 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In re Unilife Corporation, et al. [1Sect ion 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief. Signature of Debtor Date Signature of Joint Debtor Date /s/ John Ryan June 22,2017 Signature of Authorized Individual* Date John Ryan President and Chief Executive Officer Printed Name of Authorized Individu
Upvote Downvote

 
UNILIFE 8-K (Current Report/Significant Event)

2017-06-26 sec.gov
unis-8k_20170622.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2017     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)               Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
UNILIFE DEF 14A

2017-06-21 sec.gov
DEF 14A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant  þ                            Filed by a Party other than the Registrant  ¨ Check the appropriate box:   ¨   Preliminary Proxy Statement ¨   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
Upvote Downvote

 
UNILIFE EX-99.1

2017-06-21 sec.gov
EX-99.1 Exhibit 99.1 Appendix 4C Quarterly report for entities admitted on the basis of commitments Rule 4.7B Appendix 4C Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 24/10/2005 Name of entity UNILIFE CORPORATION   ARBN Quarter ended (“current quarter”) 141 042 757 31 March 15 Consolidated statement of cash flows   Cash flows related to operating activities    Current quarter $US’000     Year to date (9 months) $US’000   1.
Upvote Downvote

 
UNILIFE FORM 8-K (Current Report/Significant Event)

2017-06-21 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2015 (April 29, 2015)     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)       Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
UNILIFE EX-99.1

2017-06-21 sec.gov
EX-99.1 Exhibit 99.1   Unilife Corporation Announces Financial Results For Fiscal Year 2015 Third Quarter York, PA (May 11, 2015) Unilife Corporation (“Unilife” or “Company”) (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended March 31, 2015 (“the third quarter of Fiscal Year 2015”, “3Q FY15” or “Current Quarter”).
Upvote Downvote

 
UNILIFE 8-K (Current Report/Significant Event)

2017-06-21 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2015     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)       Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
UNILIFE SD

2017-06-21 sec.gov
SD     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM SD Specialized Disclosure Report     UNILIFE CORPORATION (Exact name of registrant as specified in its charter)       Delaware   001-34540   27-1049354 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) 250 Cross Farm Lane, York, Pennsylvania   17406 (Address of Principal Executive Offices)   (Zip Code) Alan Shortall, Chairman & Chief Executive Office
Upvote Downvote

 
UNILIFE 8-K (Current Report/Significant Event)

2017-06-20 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2015     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)       Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
UNILIFE FORM 8-K (Current Report/Significant Event)

2017-06-19 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2015     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)       Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
UNILIFE FWP

2017-06-19 sec.gov
FWP Issuer Free Writing Prospectus filed pursuant to Rule 433 supplementing the Prospectus dated October 3, 2014 Registration No. 333-197122 UNILIFE CORPORATION HAS FILED A REGISTRATION STATEMENT (REGISTRATION STATEMENT NUMBER 333- 197122) (INCLUDING A PROSPECTUS) WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION, OR THE SEC, FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS UNILIFE CORPORATIO
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

8h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...